PrEP and PEP are Prevention Act

The PrEP and PEP are Prevention Act (HR5127), introduced September 4, 2025, by Rep. Maxine Waters (D-CA) with 34 cosponsors, is currently in early legislative stages — referred to the Committees on Energy and Commerce, Ways and Means, and Oversight and Government Reform. The bill amends the Public Health Service Act, Social Security Act (Medicare, Medicaid, CHIP), and federal employee health benefits to require no-cost coverage of all FDA-approved HIV prevention drugs (PrEP and PEP), associated administrative fees, lab/diagnostic procedures, counseling, and clinical monitoring. Critically, the bill prohibits prior authorization requirements for these drugs, eliminating the most common insurer barrier to access. The money trail: This bill does NOT authorize or appropriate any federal spending. It imposes a coverage mandate on private insurers and government health programs. The financial impact flows through increased prescription volumes for drug manufacturers and increased test volumes for diagnostic laboratories. Insurers absorb the cost of the mandate — the bill shifts costs from patients to payers. For Gilead, the dominant PrEP manufacturer, this removes the $0-$50 monthly copay that suppresses patient adherence and initiation. For Labcorp, each PrEP patient generates recurring revenue from required HIV testing (every 3 months), renal panels (every 3-6 months), and STI screening — all mandated no-cost. Structural winners: Gilead ($GILD) — Descovy and Truvada hold >80% of the U.S. PrEP market; bill directly expands addressable patient population by removing financial barriers. Viatris ($VTRS) — generic TDF/FTC benefits from category expansion. Labcorp ($LH) — mandated lab monitoring creates recurring per-patient revenue stream. Losers: Health insurers (not publicly traded pure-play in this dataset) — they absorb the cost of all PrEP drugs and testing without copay revenue. Pharmacy benefit managers face reduced ability to manage PrEP drug costs via prior authorization. Real market data: $GILD trades at $129.26, down -2.74% over 7 days and -3.72% over 30 days, near the middle of its 52-week range ($95.3-$157.29). The recent 30-day decline (-3.72%) may reflect broader biotech weakness rather than PrEP-specific concerns — Gilead's HIV franchise is well-established. $VTRS at $14.82 shows +2.07% 7-day and +13.56% 30-day gains, outperforming the group. $LH at $259.57 is down -4.79% over 7 days, near the lower end of its 52-week range ($218.76-$293.72). $MRK at $110.03 is down -2.53% over 7 days and -8.02% over 30 days, approaching the low end of its 52-week range. The market has not priced in HR5127's potential — the bill is early stage and received no recent media attention. Timeline: The bill has been in committee since September 2025 with no further actions. With 34 cosponsors (all Democrats) and a Democratic sponsor, passage probability is low in the Republican-controlled 119th House (218-213 Republican majority as of 2025-2026). The bill would need committee hearings, markup, House floor vote, Senate companion introduction, Senate passage, and Presidential signature. Realistic timeline: no near-term passage. However, similar bills have been introduced in prior Congresses and could gain momentum if political control shifts in 2027.